---
layout: default
title: Mecobalamin
parent: 僅模型預測 (L5)
nav_order: 215
evidence_level: L5
indication_count: 3
---

# Mecobalamin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **3** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Mecobalamin: From Peripheral Neuropathy to Sclerosing Cholangitis

## One-Sentence Summary

Mecobalamin is an active, methylated form of Vitamin B12, globally recognized for treating peripheral neuropathy and vitamin B12 deficiency states.
The TxGNN model predicts it may be effective for **Sclerosing Cholangitis**, but there are currently **no clinical trials** and **no publications** directly supporting this direction.
Evidence is limited to model-level prediction only, and the mechanistic link is highly indirect.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No Philippines registration on record; globally recognized use: peripheral neuropathy / B12 deficiency |
| Predicted New Indication | Sclerosing Cholangitis |
| TxGNN Prediction Score | 99.50% |
| Evidence Level | L5 |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available in the system. Based on established pharmacology, Mecobalamin is the active methylcobalamin form of cobalamin (Vitamin B12). It functions as a methyl donor in the one-carbon metabolic cycle, participating in the remethylation of homocysteine to methionine via methionine synthase. This reaction is essential for DNA methylation, myelin synthesis, and cellular redox balance — which is why Mecobalamin has well-established neurological applications.

The proposed mechanistic bridge to sclerosing cholangitis is indirect: by lowering serum homocysteine, Mecobalamin could theoretically reduce oxidative stress and inflammatory signalling in biliary epithelial cells. Hyperhomocysteinaemia has been epidemiologically associated with hepatic oxidative stress and pro-fibrotic states in some observational studies, which may explain the structural proximity in the TxGNN knowledge graph.

However, sclerosing cholangitis is driven by progressive biliary fibrosis through immune-mediated mechanisms (Th17/Treg imbalance, cholangiocyte senescence, gut–liver axis dysregulation) that are mechanistically distant from the B12 methylation pathway. No in vitro, animal, or clinical study has established a causal link between Mecobalamin and biliary fibrosis resolution. This prediction reflects graph-level topology rather than validated pharmacology.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for Mecobalamin in Sclerosing Cholangitis.

---

## Literature Evidence

Currently no related literature available for Mecobalamin in Sclerosing Cholangitis.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All three TxGNN-predicted indications (Sclerosing Cholangitis, Multiple Endocrine Neoplasia, Bone Paget Disease) sit at Evidence Level L5 — knowledge graph inference with no supporting clinical, observational, or mechanistic studies. The mechanistic hypothesis for the top-ranked indication is highly speculative and does not justify further investment without foundational evidence.

**To proceed, the following is needed:**
- Retrieve full mechanism of action data from DrugBank (DB03614) to map Mecobalamin's molecular targets
- Obtain Philippines package insert to document approved warnings, contraindications, and drug interactions
- Conduct a structured literature search for B12 / homocysteine status in biliary disease populations (epidemiological signal check)
- Commission a pharmacological plausibility review: does homocysteine lowering have any measurable effect on biliary fibrosis models?
- If preclinical plausibility is confirmed, design a targeted in vitro study before considering any clinical pathway
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

